Literature DB >> 18460045

Cognitive fMRI and soluble telencephalin assessment in patients with localization-related epilepsy.

J F A Jansen1, M C G Vlooswijk, M H de Baets, M C T F M de Krom, P Rieckmann, W H Backes, A P Aldenkamp.   

Abstract

Objectives - The use of telencephalin as a possible marker for altered cortical function as demonstrated by functional MRI was investigated in a pilot study with 16 patients with localization-related epilepsy and secondarily generalized seizures. Materials and methods - Functional MRI of verbal working memory performance (Sternberg paradigm) and self-regulatory control processes (Stroop paradigm) was used to examine cortical activation in 16 patients with localization-related epilepsy and secondarily generalized seizures. Additionally, blood serum concentrations of soluble telencephalin (marker for neuronal damage) were determined. Results - In three patients (one temporal and two frontal focus), telencephalin was detected. All three patients had lower functional MRI activation in the frontotemporal region (P = 0.04), but not in other regions (P > 0.35) compared with patients without detectable telencephalin. Additionally, an association of levetiracetam and frontotemporal activation was observed. Conclusions - These preliminary data in a heterogeneous group suggest an association between decreased frontotemporal activation on fMRI and both detectable telencephalin serum levels and levetiracetam use. Future longitudinal studies with larger patient groups are required to confirm these observations. It is hypothesized that altered local function of the frontotemporal cortex in localization-related epilepsy might be better predicted by the biochemical marker telencephalin than epilepsy characteristics such as seizure focus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460045     DOI: 10.1111/j.1600-0404.2008.01005.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas.

Authors:  Ryan P Lange; Allen Everett; Pratima Dulloor; Frederick K Korley; Chetan Bettegowda; Cherie Blair; Stuart A Grossman; Matthias Holdhoff
Journal:  Cancer Invest       Date:  2014-07-14       Impact factor: 2.176

2.  The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy.

Authors:  John R Pollard; Ofer Eidelman; Gregory P Mueller; Clifton L Dalgard; Peter B Crino; Christopher T Anderson; Elizabeth J Brand; Evren Burakgazi; Sai K Ivaturi; Harvey B Pollard
Journal:  Front Neurol       Date:  2013-01-03       Impact factor: 4.003

3.  Structure, Expression, and Function of ICAM-5.

Authors:  Heping Yang
Journal:  Comp Funct Genomics       Date:  2012-01-23

4.  Telencephalin protects PAJU cells from amyloid beta protein-induced apoptosis by activating the ezrin/radixin/moesin protein family/phosphatidylinositol-3-kinase/protein kinase B pathway.

Authors:  Heping Yang; Dapeng Wu; Xiaojie Zhang; Xiang Wang; Yi Peng; Zhiping Hu
Journal:  Neural Regen Res       Date:  2012-10-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.